Just for clarification the research by Wilton and Fletcher which led to the development of a therapy for DMD was conducted at The University of WA. I understand that the licensing agreement to develop exon-skipping drugs for DMD was signed between Sarepta and the UWA. The financial terms of that landmark agreement may hold some significance in looking at commercial deals between biotechnology companies and academic institutions.
Just for clarification the research by Wilton and Fletcher which...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
0.005(0.40%) |
Mkt cap ! $740.7M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.29 | $1.27 | $406.0K | 319.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13987 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 1380 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |